MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Cardiovascular, Cardiac & Cardiology Companies _ Congestive Heart Failure (CHF)
scPharmaceuticals Inc. (NASDAQ: SCPH) _Infused therapies*
Organization & Developments: scPharmaceuticals
Parents
scPharmaceuticals Inc. (NASDAQ: SCPH) _Infused therapies*
Children
*Pharmaceutical company focused on developing products to optimize the delivery of infused therapies
*The company is focused on subcutaneous drug administration products, which is an optimized way to deliver infused therapies available through intravenous administration
*The company’s flagship product, FUROSCIX (furosemide), is an injectable treatment for heart failure that was FDA-approved in October 2022. FUROSCIX is currently marketed for heart failure patients and is delivered via an 80mg/1ml auto-injector.
2018: ScPharmaceuticals: Time For The PDUFA Run-Up_seekingalpha.com
2019: The company received a CRL for its original application for this indication and is in the midst of conducting additional studies with the goal of refiling its NDA in 2020
2020: scPharmaceutical Slidedeck_seekingalpha_attachment
2022: scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients_seekingalpha.com
2023: scPharmaceuticals Q3 Earnings: Cruising Toward Success
2025: scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025
Jumps
Finance & Acquisitions: scPharmaceuticals
Key People: scPharmaceuticals